27610217|t|Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting
27610217|a|Asthma affects an estimated 300 million people worldwide with the condition associated with significant healthcare utilisation costs and a large impact on patient quality of life. The SQ(®) HDM SLIT-tablet (ACARIZAX(®), Hørsholm, Denmark) is a sublingually administered allergy immunotherapy tablet for house dust mite allergic asthma and allergic rhinitis and has recently been licensed in Europe. To assess the cost-effectiveness of ACARIZAX plus pharmacotherapy versus placebo plus pharmacotherapy in patients with house dust mite allergic asthma that is uncontrolled by inhaled corticosteroids, in a German setting. Eligible patients should also have symptoms of mild to severe allergic rhinitis. A cost utility analysis was undertaken, based on the results of a European phase III randomised controlled trial, in which ACARIZAX was compared with placebo with both treatment groups also receiving pharmacotherapy in the form of inhaled corticosteroids and short-acting β2-agonists. Cost and quality-adjusted life years from the trial were extrapolated over a nine year time horizon and the incremental cost-effectiveness ratio calculated to compare treatment options. ACARIZAX plus pharmacotherapy was estimated to generate 6.16 quality-adjusted life years per patient at a cost of €5658, compared with 5.50 quality-adjusted life years (QALYs) at a cost of €2985 for placebo plus pharmacotherapy. This equated to an incremental cost of €2673, incremental QALYs of 0.66 and an incremental cost-effectiveness ratio (ICER) of €4041. The ICER was, therefore, substantially lower than the €40,000 willingness-to-pay threshold per QALY adopted for the analysis. Deterministic sensitivity analyses indicate the results are most sensitive to the utility score of ACARIZAX patients during years 2 and 3 of treatment. This analysis indicates that ACARIZAX plus pharmacotherapy is cost-effective compared with placebo plus pharmacotherapy for house dust mite allergic asthma patients in Germany. If a disease-modifying effect can be proven the results of this analysis may underestimate the true benefits of ACARIZAX.
27610217	29	50	SQ(®) HDM SLIT-tablet	T103	UMLS:C0013227
27610217	54	69	house dust mite	T204	UMLS:C0998367
27610217	70	85	allergic asthma	T038	UMLS:C0155877
27610217	100	106	German	T098	UMLS:C1556085
27610217	115	121	Asthma	T038	UMLS:C0004096
27610217	155	161	people	T098	UMLS:C0027361
27610217	299	320	SQ(®) HDM SLIT-tablet	T103	UMLS:C0013227
27610217	345	352	Denmark	T082	UMLS:C0011318
27610217	385	392	allergy	T038	UMLS:C0020517
27610217	393	406	immunotherapy	T058	UMLS:C0021083
27610217	407	413	tablet	T103	UMLS:C0013227
27610217	418	433	house dust mite	T204	UMLS:C0998367
27610217	434	449	allergic asthma	T038	UMLS:C0155877
27610217	454	471	allergic rhinitis	T038	UMLS:C2607914
27610217	494	502	licensed	T170	UMLS:C0023636
27610217	506	512	Europe	T082	UMLS:C0015176
27610217	550	563	ACARIZAX plus	T103	UMLS:C0013227
27610217	564	579	pharmacotherapy	T058	UMLS:C0013216
27610217	587	599	placebo plus	T103	UMLS:C0013227
27610217	600	615	pharmacotherapy	T058	UMLS:C0013216
27610217	633	648	house dust mite	T204	UMLS:C0998367
27610217	649	664	allergic asthma	T038	UMLS:C0155877
27610217	689	712	inhaled corticosteroids	T103	UMLS:C0001617
27610217	719	725	German	T098	UMLS:C1556085
27610217	770	778	symptoms	T033	UMLS:C1457887
27610217	797	814	allergic rhinitis	T038	UMLS:C2607914
27610217	882	890	European	T098	UMLS:C1535514
27610217	891	928	phase III randomised controlled trial	T062	UMLS:C0206035
27610217	939	947	ACARIZAX	T103	UMLS:C0013227
27610217	966	973	placebo	T103	UMLS:C0013227
27610217	984	993	treatment	T058	UMLS:C0087111
27610217	994	1000	groups	T098	UMLS:C1257890
27610217	1016	1031	pharmacotherapy	T058	UMLS:C0013216
27610217	1047	1070	inhaled corticosteroids	T103	UMLS:C0001617
27610217	1075	1099	short-acting β2-agonists	T103	UMLS:C2936789
27610217	1147	1152	trial	T062	UMLS:C0008976
27610217	1268	1285	treatment options	T058	UMLS:C0683525
27610217	1287	1300	ACARIZAX plus	T103	UMLS:C0013227
27610217	1301	1316	pharmacotherapy	T058	UMLS:C0013216
27610217	1486	1498	placebo plus	T103	UMLS:C0013227
27610217	1499	1514	pharmacotherapy	T058	UMLS:C0013216
27610217	1765	1773	analysis	T062	UMLS:C0936012
27610217	1775	1809	Deterministic sensitivity analyses	T062	UMLS:C0936012
27610217	1874	1882	ACARIZAX	T103	UMLS:C0013227
27610217	1916	1925	treatment	T058	UMLS:C0087111
27610217	1932	1940	analysis	T062	UMLS:C0936012
27610217	1956	1969	ACARIZAX plus	T103	UMLS:C0013227
27610217	1970	1985	pharmacotherapy	T058	UMLS:C0013216
27610217	2018	2030	placebo plus	T103	UMLS:C0013227
27610217	2031	2046	pharmacotherapy	T058	UMLS:C0013216
27610217	2051	2066	house dust mite	T204	UMLS:C0998367
27610217	2067	2082	allergic asthma	T038	UMLS:C0155877
27610217	2095	2102	Germany	T082	UMLS:C0017480
27610217	2168	2176	analysis	T062	UMLS:C0936012
27610217	2216	2224	ACARIZAX	T103	UMLS:C0013227